



March 6, 2018

Radius Health to Present at the Cowen 38th Annual Health Care Conference

WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen's 38th Annual Health Care Conference on Monday, March 12, 2018.

Information on the presentation is as follows:

Event: Cowen 38th Annual Health Care Conference
Date: Monday, March 12, 2018
Time: 3:30 p.m. EDT
Location: Dartmouth Room, 3rd Floor, Boston Marriott Copley Place, Boston, MA

A live webcast of the presentation will be available by visiting the Investors section of Radius' website at <http://ir.radiuspharm.com/events.cfm>. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.

About Radius Health

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com, and follow us on [Twitter](#) and [LinkedIn](#).

Investor Relations Contact:

Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011